BGLAF (BioGaia AB) ROE % Adjusted to Book Value: 2.94% (As of Mar. 2026)

BioGaia AB BGLAF 100 ROE % Adjusted to Book Value is 2.94% as of Mar. 2026. GuruFocus rates BGLAF with a GF Score™ of 100/100 and a GF Value™ of $13.05. The stock has 5 warning signs investors should review.

BioGaia AB's ROE % for the quarter that ended in Mar. 2026 was 23.35%. BioGaia AB's PB Ratio for the quarter that ended in Mar. 2026 was 7.93. BioGaia AB's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 2.94%.

BioGaia AB ROE % Adjusted to Book Value Related Terms

BioGaia AB ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for BioGaia AB's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioGaia AB ROE % Adjusted to Book Value Chart

BioGaia AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

1.90

3.41

3.61

2.92

3.07

BioGaia AB Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															3.45	3.10	2.76	4.00	2.94

BGLAF vs ZTS: ROE % Adjusted to Book Value Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioGaia AB ROE % Adjusted to Book Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where BioGaia AB's ROE % Adjusted to Book Value falls into.

Save Embed

100GF Score

BioGaia AB BGLAF

ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

BioGaia AB ROE % Adjusted to Book Value Calculation

BioGaia AB's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	24.00%	/	7.83
	=	3.07%

BioGaia AB's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	23.35%	/	7.93
	=	2.94%

Frequently Asked Questions Learn more about ROE % Adjusted to Book Value →

What does a ROE % Adjusted to Book Value of 2.94% mean?

BioGaia AB (BGLAF) has a ROE % Adjusted to Book Value of 2.94% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on BioGaia AB and its competitors.

Is BioGaia AB's ROE % Adjusted to Book Value too high?

BioGaia AB's current ROE % Adjusted to Book Value is 2.94%. Overall, BioGaia AB has a GF Score™ of 100/100, reflecting its overall financial health beyond just this single metric.

How does BioGaia AB's ROE % Adjusted to Book Value compare to ZTS?

BioGaia AB's ROE % Adjusted to Book Value of 2.94% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?

A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROE % Adjusted to Book Value mean?

A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on BioGaia AB and its competitors. BioGaia AB's current ROE % Adjusted to Book Value is 2.94%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is BioGaia AB stock overvalued right now?

BioGaia AB (BGLAF) has a current ROE % Adjusted to Book Value of 2.94%. The stock's GF Value™ is $13.05, compared to a current price of $12.20 — trading 6.5% below its estimated fair value. The current ROE % Adjusted to Book Value is 2.94%. BioGaia AB's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROE % Adjusted to Book Value calculated?

ROE % Adjusted to Book Value is calculated from a company's financial statements. For BioGaia AB (BGLAF), the current ROE % Adjusted to Book Value is 2.94% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioGaia AB (BGLAF) Overvalued in 2026?

Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued. The current stock price of $12.20 is trading 6.5% below its estimated GF Value™ of $13.05.

Key valuation signals for BGLAF:

ROE % Adjusted to Book Value: 2.94%
GF Value™: $13.05 vs. price of $12.20 (6.5% below fair value)
GF Score™: 100/100 with 5 warning signs

No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioGaia AB Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies OSTO:CRNO B OSTO:NANEXA OSTO:EQL OSTO:ORX OSTO:ENZY OSTO:CINPHA OSTO:MOB OSTO:DICOT OSTO:KLAR XSAT:ACUC XTER:MRK TSE:4502 XSWX:GALD SHSE:600276 NSE:SUNPHARMA XTAE:TEVA LSE:HLN XSWX:SDZ ZTS HKSE:03692

Other Exchanges BIOG B:Sweden 0GTN:UK BGLA:Germany

Address Kungsbroplan 3A, Stockholm, SWE, SE-112 27

Website https://www.biogaiagroup.com

BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).

100GF Score

Get the complete analysis for BGLAF

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.20

Price

$13.05

GF Value

View BGLAF Analysis

See ROE % Adjusted to Book Value data for all stocks →